The API-CAT trial (Apixaban Cancer-Associated Thrombosis) demonstrated that, in patients with active cancer who had completed ...
ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One ...
Patients with A-fib and only one of the three dose-reduction criteria used in the ARISTOTLE trial—age 80 years or older, body weight 60 kg or less, and creatinine level 1.5 mg/dL or higher—have higher ...
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...
DURHAM, NC — A secondary analysis of the ARISTOTLE trial supports using the standard 5-mg twice-daily dose of apixaban (Eliquis, Bristol-Myers Squibb) in patients with atrial fibrillation (AF) who ...
PRINCETON, N.J. & NEW YORK, Jun 27, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY -0.74% and Pfizer Inc. PFE -0.14% today announced that the Committee for Medicinal Products for Human Use ...
PRINCETON, NJ — One lot of apixaban (Eliquis, Bristol-Myers Squibb) 5-mg tablets is being voluntarily recalled after a consumer complained that a bottle labeled as Eliquis 5 mg actually contained ...
Rivaroxaban once daily and dabigatran twice daily showed evidence of lower thromboembolic rates. Apixaban 2.5 mg twice daily was associated with higher rates of ischemic stroke or systemic embolism ...
In the ARISTOTLE trial of apixaban versus warfarin for stroke prevention in patients with atrial fibrillation, those with two or more dose-reduction criteria (aged ≥80 years, weight ≤60 kg, creatinine ...
Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...
Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results